GlaxoSmithKline plc (GSK) Earns “Neutral” Rating from JPMorgan Chase & Co.
GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reissued by stock analysts at JPMorgan Chase & Co. in a research note issued on Wednesday. They presently have a GBX 1,667 ($20.32) price target on the stock.
A number of other research firms have also issued reports on GSK. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, July 27th. Bryan, Garnier & Co reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday. BNP Paribas reiterated a “neutral” rating and issued a GBX 1,430 ($17.43) target price on shares of GlaxoSmithKline plc in a research note on Sunday, July 3rd. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a GBX 1,800 ($21.94) target price on shares of GlaxoSmithKline plc in a research note on Tuesday, July 12th. Finally, Morgan Stanley raised their target price on shares of GlaxoSmithKline plc from GBX 1,500 ($18.28) to GBX 1,650 ($20.11) and gave the company an “equal weight” rating in a research note on Monday, July 11th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc has an average rating of “Hold” and a consensus price target of GBX 1,677.42 ($20.44).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1667.00 on Wednesday. The company’s 50 day moving average is GBX 1,651.49 and its 200-day moving average is GBX 1,567.94. The company’s market cap is GBX 81.03 billion. GlaxoSmithKline plc has a 12 month low of GBX 1,277.25 and a 12 month high of GBX 1,745.56.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/glaxosmithkline-plc-gsk-earns-neutral-rating-from-jpmorgan-chase-co.html
The business also recently disclosed a dividend, which was paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th were given a GBX 19 ($0.23) dividend. This represents a yield of 1.12%. The ex-dividend date of this dividend was Thursday, August 11th.
In other GlaxoSmithKline plc news, insider Slaoui,Moncef purchased 28 shares of the stock in a transaction dated Friday, August 12th. The stock was bought at an average price of GBX 2,208 ($26.91) per share, for a total transaction of £618.24 ($753.49). Also, insider Witty,Sir Andrew P sold 10,000 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.63), for a total transaction of £169,300 ($206,337.60).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.